Hernández-Espinosa David, Ordóñez Adriana, Miñano Antonia, Martínez-Martínez Irene, Vicente Vicente, Corral Javier
Centro Regional de Hemodonación, University of Murcia, Murcia, Spain.
Thromb Res. 2009 Sep;124(4):483-9. doi: 10.1016/j.thromres.2009.05.020. Epub 2009 Jul 2.
Recent data support that diabetes might be a conformational disease. Certainly, hyperglycaemia causes a broad range of deleterious effects that might facilitate protein aggregation. We have evaluated the effects of hyperglycaemia on antithrombin, a conformationally sensitive serpin with a potent anticoagulant role. Moreover, these studies might also help to understand the thrombotic risk associated to diabetes. We incubated in vitro plasma and purified antithrombin and human hepatoma cells (HepG2) with methyl-glyoxal and glucose. Moreover, a mouse model of acute diabetes was generated with streptozotocin. Antigen, anti-FXa activity, heparin affinity and conformational features of antithrombin were analysed. Histological and intracellular features and distribution of antithrombin in HepG2 and livers of mice were also evaluated. Hyperglycaemia in vitro induced a transition of antithrombin to a form with low heparin affinity that explained the loss of anticoagulant activity, without generation of abnormal conformers (polymers or latent antithrombin). However, these effects were not observed on circulating antithrombin from diabetic mice. In contrast, hyperglycaemia in vivo had significant effects on intracellular antithrombin, which was retained, forming microaggregates within the lumen of dilated cisterns of the endoplasmic reticulum. These effects explained the moderate type I deficiency observed in diabetic mice. Similar intracellular consequences were observed for another hepatic serpin, alpha1-antitrypsin. Our data further support that diabetes has conformational effects on structurally sensitive proteins. These effects on antithrombin, the main natural anticoagulant, might contribute to the hypercoagulable status of diabetic patients.
近期数据支持糖尿病可能是一种构象疾病。当然,高血糖会引发一系列有害影响,这可能会促进蛋白质聚集。我们评估了高血糖对抗凝血酶的影响,抗凝血酶是一种对构象敏感的丝氨酸蛋白酶抑制剂,具有强大的抗凝作用。此外,这些研究或许也有助于理解与糖尿病相关的血栓形成风险。我们在体外将血浆、纯化的抗凝血酶以及人肝癌细胞(HepG2)与甲基乙二醛和葡萄糖一起孵育。此外,用链脲佐菌素建立了急性糖尿病小鼠模型。分析了抗凝血酶的抗原、抗凝血因子Xa活性、肝素亲和力及构象特征。还评估了抗凝血酶在HepG2细胞和小鼠肝脏中的组织学和细胞内特征及分布。体外高血糖诱导抗凝血酶转变为一种肝素亲和力低的形式,这解释了抗凝活性的丧失,且未产生异常构象(聚合物或潜在抗凝血酶)。然而,在糖尿病小鼠的循环抗凝血酶上未观察到这些效应。相反,体内高血糖对细胞内抗凝血酶有显著影响,抗凝血酶被滞留在内质网扩张池腔内形成微聚集体。这些效应解释了在糖尿病小鼠中观察到的中度I型缺乏。对于另一种肝脏丝氨酸蛋白酶抑制剂α1-抗胰蛋白酶也观察到了类似的细胞内后果。我们的数据进一步支持糖尿病对结构敏感蛋白具有构象影响。这些对主要天然抗凝剂抗凝血酶的影响可能导致糖尿病患者的高凝状态。